Wells Fargo Maintains Overweight on Enovis, Lowers Price Target to $40

Benzinga Newsdesk www.benzinga.com Negative 78.6%

Neg 78.6% Neu 0% Pos 0%

Wells Fargo analyst Larry Biegelsen maintains Enovis (NYSE:ENOV) with a Overweight and lowers the price target from $42 to $40.